Transforming cancer treatment and advancing new therapies through empowered science

Webcast ImageWebcast
4th Quarter 2014 Financial Results (Live)
02/10/15 at 1:30 p.m. PT
4th Quarter 2014 Financial Results
Tuesday, February 10, 2015 1:30 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.

The company’s lead product, ADCETRIS® (brentuximab vedotin) is an ADC that, in collaboration with Takeda Pharmaceutical Company Limited is commercially available for two indications in more than 45 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage ADC programs designed to address the unmet medical needs of people with cancer, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME and ASG-15ME. Seattle Genetics’ ADC technology is employed by a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. Across both internal and collaborator programs, there are 25 ADCs in clinical development using our proprietary approach to empowering antibodies.

Download Documentation  Corporate Fact Sheet
Download Documentation  2013 Annual Report
Download Documentation  2014 Proxy Statement
Investor Contact
Peggy Pinkston
Senior Director, Corporate Communications
PHONE: (425) 527-4160
FAX: (425) 527-4001
EMAIL: ppinkston@seagen.com

Media Contact
Tricia Larson
Director, Public Relations
PHONE: 425-527-4180
EMAIL: tlarson@seagen.com
Stock Quote
SGEN (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$31.74
Change (%) Stock is Down 1.47 (4.40%)
Volume739,900
Data as of 01/28/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >
DateTitle 
01/21/15Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2014 Financial Results on February 10, 2015
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 21, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its fourth quarter and year 2014 financial results on Tuesday, February 10, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE a... 
Printer Friendly Version
01/12/15Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies
BOTHELL, Wash. & NEW YORK--(BUSINESS WIRE)--Jan. 12, 2015-- Seattle Genetics, Inc. (Nasdaq:SGEN) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that the companies have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in two planned Phase 1/2 ... 
Printer Friendly Version
01/06/15Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 6, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015, at 11:30 a.m. Pacific Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. ... 
Printer Friendly Version
12/18/14Seattle Genetics Initiates Phase 1b Trial of SGN-CD33A in Combination with Frontline Standard of Care and as Consolidation Therapy for Acute Myeloid Leukemia
-SGN-CD33A is an Antibody-Drug Conjugate (ADC) Utilizing Seattle Genetics’ Newest ADC Technology- BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 18, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced initiation of a phase 1b clinical trial of SGN-CD33A in combination with standard of care chemotherapy, including cytarabine and daunorubicin, for patients with newly diagnosed acute myeloid leukemia (AML). The trial will also evaluate SGN... 
Printer Friendly Version
12/08/14Seattle Genetics Presents Data from Novel Antibody-Drug Conjugate SGN-CD33A at ASH Annual Meeting
First Clinical Data Presentation of SGN-CD33A Demonstrates Encouraging Antitumor Activity in Acute Myeloid Leukemia; Dose and Schedule Refinement Ongoing Phase 1b Combination Trial Planned to Evaluate SGN-CD33A with Standard of Care in Frontline and Consolidation Settings for Acute Myeloid Leukemia SAN FRANCISCO--(BUSINESS WIRE)--Dec. 8, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) today presented data from an ongoing phas... 
Printer Friendly Version
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.